Can you Re-Dose AAV at High Vector Doses?

Time: 2:15 pm
day: Pre-Conference Day

Details:

• The ability to administer multiple doses of AAV vector could provide a potential strategy to mitigate toxicities typically associated with vector doses of 1E14 vg/kg or higher
• However, such a strategy would require the ability to re-dose at vector doses of ~5E13 vg/kg, which presents a considerable immunological challenge
• Presenting data to investigate combination treatment using ImmTOR tolerogenic nanoparticle to mitigate immune responses to high vector doses

Speakers:

Kei Kishimoto Kei Kishimoto is the Chief Scientific Officer of Selecta Bioscience, a clinical stage company completing Phase 3 trials of its ImmTOR tolerogenic nanoparticle technology. Kei Read more